Fundraising Fox

TFF Pharmaceuticals

Austin, US · Founded 2018 · Delaware corporation

Biotech

Founders & leadership

BW
Brian WindsorNamed on SEC filing
KC
Kirk ColemanNamed on SEC filing
RS
Robert S. Mills, Jr.Named on SEC filing
AF
Aaron FletcherNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$48.2M disclosed across 3 of 4 rounds · 2018–2024

▶$1.2MofferedApr 2024 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • BRANDI ROBERTSDirector
  • THOMAS KINGDirector
  • ROBERT S. MILLS, JR.Director
  • STEPHEN ROCAMBOLIDirector
  • HARLAN WEISMANExecutive Officer, Director
  • ZAMANEH MIKHAKExecutive Officer
  • KIRK COLEMANExecutive Officer
  • MICHAEL PATANEDirector
  • CATHERINE LEEDirector
Offering amount
$1.2M
Sales commissions
$82.6K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25.9MraisedAug 2020 · 23 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • RANDY THURMANDirector
  • MALCOLM FAIRBAIRNDirector
  • HARLAN WEISMANDirector
  • BRIAN WINDSORExecutive Officer, Director
  • STEPHEN ROCAMBOLIDirector
  • AARON FLETCHERDirector
  • KIRK COLEMANExecutive Officer
  • ROBERT S. MILLS, JR.Director
  • GLENN MATTESExecutive Officer, Director
Offering amount
$25.9M
Amount sold
$25.9M
Sales commissions
$1.6M
Placement agents
Jefferies LLC
First sale
Aug 2020
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.2MraisedJul 2019 · 229 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • ROBERT S. MILLS, JR.Director
  • BRIAN WINDSORDirector
  • KIRK COLEMANExecutive Officer
  • RANDY THURMANDirector
  • GLENN MATTESExecutive Officer, Director
  • STEPHEN ROCAMBOLIDirector
  • HARLAN WEISMANDirector
  • AARON FLETCHERDirector
Offering amount
$8.2M
Amount sold
$8.2M
Minimum investment
$10K
Sales commissions
$817K
Placement agents
NATIONAL SECURITIES CORPORATION
First sale
May 2019
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$14.2MraisedMar 2018 · 224 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Brian WindsorExecutive Officer, Director
  • Kirk ColemanExecutive Officer
  • Robert S. Mills, Jr.Executive Officer, Director
  • Aaron FletcherDirector
Offering amount
$14.2M
Amount sold
$14.2M
Minimum investment
$10K
Sales commissions
$1.4M
Placement agents
National Securities Corporation
First sale
Mar 2018
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Robinhood4 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits3 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.

Companies competing with TFF Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2023$864.9K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Programfinance.yahoo.com · May 2023Austin's TFF Pharmaceuticals raises $25.9M with stock offeringeu.statesman.com · Aug 2020TFF Pharmaceuticals raises $22 million pricing IPO at $5 | Nasdaqnasdaq.com · Oct 2019TFF Pharmaceuticals Raises $8.17 Million and Expands Leadership Team with New CFO and Director Appointments - BioSpacebiospace.com · May 2019TFF Pharmaceuticals Raises $14M in Series A Financing - FinSMEsfinsmes.com · Apr 2018

Frequently asked questions

How much funding has TFF Pharmaceuticals raised?
TFF Pharmaceuticals has disclosed $48.2M raised across 3 of its 4 known rounds.
Where is TFF Pharmaceuticals headquartered?
TFF Pharmaceuticals is headquartered in Austin, US.